Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry. Issue 6 (2nd June 2016)

• Record Type: Journal Article
• Authors: Song, Dongjian; Yue, Lifang; Zhang, Junjie; Ma, Shanshan; Zhao, Wei; Guo, Fei; Fan, Yingzhong; Yang, Heying; Liu, Qiuliang; Zhang, Da; Xia, Ziqiang; Qin, Pan; Jia, Jia; Yue, Ming; Yu, Jiekai; Zheng, Shu; Yang, Fuquan; Wang, Jiaxiang
• Is Part Of: Cancer biology & therapy. Volume 17:Issue 6(2016)
• Page Start: 635
• Page End: 647
• Publication Date: 2016-06-02
• Subjects: Apolipoprotein C-I -- breast cancer -- biomarker -- diagnosis -- mass spectrometry -- prognosis -- serum; 616.99406
• DOI: 10.1080/15384047.2016.1156262
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Women with triple-negative breast cancer (TNBC) have poor prognosis because of the aggressive nature of the tumor, delayed diagnosis and non-specific symptoms in the early stages. Identification of novel specific TNBC serum biomarkers for screening and therapeutic purposes therefore remains an urgent clinical requirement.We obtained serum samples from a total of 380 recruited individuals split into mining and testing sets, with the aim of screening for reliable protein biomarkers from TNBC and non-TNBC (NTNBC) sera. Samples were assessed using mass spectrometry, followed by receiver operating characteristic (ROC), survival and hazard function curve as well as multivariate Cox regression analyses to ascertain the potential of the protein constituents as diagnostic and prognostic biomarkers for TNBC.We identified upregulated apolipoprotein C-I (apoC-I) with a validated positive effect on TNBC tumorigenesis, with confirmation in an independent test set and minimization of systematic bias by pre-analytical parameters. The apoC-I protein had superior diagnostic ability in distinguishing between TNBC and NTNBC cases. Moreover, the protein presented a more robust potential prognostic factor for TNBC than NTNBC. The apoC-I protein identified in this study presents an effective novel diagnostic and prognostic biomarker for TNBC, indicating that measurement of the peak intensity at 7785 Da in serum samples could facilitate improved early detection and estimation of postoperative survival prognosis for TNBC.